Topics

NICE approves palbociclib with fulvestrant on the CDF for treatment of some breast cancers

06:49 EST 15 Jan 2020 | European Pharmaceutical Review

The NICE committee has made palbociclib with fulvestrant available on the Cancer Drug Fund for patients with hormone receptor-positive, HER2-negative, advanced breast cancer.

The post NICE approves palbociclib with fulvestrant on the CDF for treatment of some breast cancers appeared first on European Pharmaceutical Review.

Original Article: NICE approves palbociclib with fulvestrant on the CDF for treatment of some breast cancers

NEXT ARTICLE

More From BioPortfolio on "NICE approves palbociclib with fulvestrant on the CDF for treatment of some breast cancers"

Quick Search

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...